KR20230042598A - SARS-CoV-2 중화 항체 또는 그 단편 - Google Patents

SARS-CoV-2 중화 항체 또는 그 단편 Download PDF

Info

Publication number
KR20230042598A
KR20230042598A KR1020237008579A KR20237008579A KR20230042598A KR 20230042598 A KR20230042598 A KR 20230042598A KR 1020237008579 A KR1020237008579 A KR 1020237008579A KR 20237008579 A KR20237008579 A KR 20237008579A KR 20230042598 A KR20230042598 A KR 20230042598A
Authority
KR
South Korea
Prior art keywords
ser
amino acid
chain variable
seq
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237008579A
Other languages
English (en)
Korean (ko)
Inventor
마사루 타게시타
츠토무 타케우치
카츠야 스즈키
히데유키 사야
요시마사 타카하시
사야 모리야마
히데히로 후쿠야마
치에코 오카무라
미카코 시로우즈
타케히사 마츠모토
카츠히코 카마다
야스시 이토
히로히토 이시가키
미사코 나카야마
요시노리 키타가와
요시히로 카와오카
Original Assignee
각고호우징 게이오기주크
고쿠리쯔 간센쇼 겐큐쇼쵸가 다이효스루 니혼고꾸
리켄
고쿠리츠다이가쿠호진 시가 이카다이가쿠
고쿠리츠다이가쿠호우진 도쿄다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 각고호우징 게이오기주크, 고쿠리쯔 간센쇼 겐큐쇼쵸가 다이효스루 니혼고꾸, 리켄, 고쿠리츠다이가쿠호진 시가 이카다이가쿠, 고쿠리츠다이가쿠호우진 도쿄다이가쿠 filed Critical 각고호우징 게이오기주크
Publication of KR20230042598A publication Critical patent/KR20230042598A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
KR1020237008579A 2020-09-25 2021-09-24 SARS-CoV-2 중화 항체 또는 그 단편 Withdrawn KR20230042598A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020161205 2020-09-25
JPJP-P-2020-161205 2020-09-25
JPJP-P-2021-012394 2021-01-28
JP2021012394 2021-01-28
PCT/JP2021/035159 WO2022065445A1 (ja) 2020-09-25 2021-09-24 ＳＡＲＳ－ＣｏＶ－２中和抗体又はその断片

Publications (1)

Publication Number Publication Date
KR20230042598A true KR20230042598A (ko) 2023-03-28

Family

ID=80846662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237008579A Withdrawn KR20230042598A (ko) 2020-09-25 2021-09-24 SARS-CoV-2 중화 항체 또는 그 단편

Country Status (6)

Country Link
US (1) US20230348573A1 (https=)
EP (1) EP4219548A1 (https=)
JP (1) JPWO2022065445A1 (https=)
KR (1) KR20230042598A (https=)
CN (1) CN116249711A (https=)
WO (1) WO2022065445A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019110A1 (ja) * 2022-07-20 2024-01-25 国立感染症研究所長が代表する日本国 ＳＡＲＳ－ＣｏＶ－２に対する抗体
WO2024053719A1 (ja) * 2022-09-08 2024-03-14 国立大学法人熊本大学 コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
WO2024151583A2 (en) * 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7481994B2 (ja) 2018-12-17 2024-05-13 カシオ計算機株式会社 信号検出装置、信号検出方法及び信号検出プログラム
JP7159094B2 (ja) 2019-03-27 2022-10-24 日本発條株式会社 ディスク装置のカバー構造
CN111423508A (zh) * 2020-03-31 2020-07-17 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种分离的抗病毒感染的SARS-CoV-2蛋白结合分子
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN111620946B (zh) * 2020-05-09 2020-12-22 江苏省疾病预防控制中心(江苏省公共卫生研究院) 分离的新型冠状病毒单克隆抗体或其抗原结合部分
CN111560070B (zh) * 2020-05-27 2021-10-01 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用
CN111647077B (zh) * 2020-06-02 2021-02-09 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
CN111690059B (zh) * 2020-06-19 2022-03-08 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1D7

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
비특허 문헌 1: Martin R Gaudinski, et al., Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein(VRC608): an open-label phase 1 study, Lancet, 393(10174), 889-898, 2019.
비특허 문헌 10: Seth J. Zost, et al., Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein, Nature Medicine, 26, 1422-1427, 2020.
비특허 문헌 11: Seth J. Zost, et al., Potently neutralizing and protective human antibodiesa gainst SARS-CoV-2, Nature, 584, 443-449, 2020.
비특허 문헌 12: Lihong Liu, et al., Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, Nature, 584, 450-456, 2020.
비특허 문헌 2: Peng Zhou, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270-273, 2020.
비특허 문헌 3: Jenna J. Guthmiller, et al., An Efficient Method to Generate Monoclonal Antibodies from Human B Cells, Methods Mol Biol., 1904, 109-145, 2019.
비특허 문헌 4: Masaru Takeshita, et al., Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands, Ann Rheum Dis., 79(1), 150-158, 2020.
비특허 문헌 5: John J. Trombetta, et al., Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing, Curr Protoc Mol Biol., 107, 4.22.1-4.22.17, 2014.
비특허 문헌 6: Rui Shi, et al., A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, Nature, 584, 120-124, 2020.
비특허 문헌 7: Xiangyang Chi, et al., A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2, Science, 369(6504), 650-655, 2020.
비특허 문헌 8: Thomas F Rogers, et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, Science, 369(6506), 956-963, 2020.
비특허 문헌 9: Bin Ju, et al., Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 584, 115-119, 2020.

Also Published As

Publication number Publication date
US20230348573A1 (en) 2023-11-02
CN116249711A (zh) 2023-06-09
EP4219548A1 (en) 2023-08-02
JPWO2022065445A1 (https=) 2022-03-31
WO2022065445A1 (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
CN108064240B (zh) 针对流感血凝素的人抗体
KR101516569B1 (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
AU2013256251C1 (en) Human antibodies to Fel d1 and methods of use thereof
KR101418606B1 (ko) Ｈｅｒ-３ 지향 항체 및 그 용도
KR102695416B1 (ko) 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
AU2017345786B2 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN115315443A (zh) 抗sars-cov-2抗体和其用途
TW202235432A (zh) 中和抗ｓａｒｓ－ｃｏｖ－２抗體
TWI854285B (zh) 抗體介導屈公(chikungunya)病毒中和
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
KR20190030206A (ko) 항-지카 바이러스 항체 및 사용 방법
CN114685652B (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
CA2508375A1 (en) Antibodies directed to tumor necrosis factor and uses thereof
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
KR20230142790A (ko) 코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
KR20230042598A (ko) SARS-CoV-2 중화 항체 또는 그 단편
KR20220098003A (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR20220054080A (ko) SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
CN114573690B (zh) 抗sar-cov-2全人源单克隆抗体及其制法与应用
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

WITB Written withdrawal of application
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000